DXBDIMERIX LIMITED
Announcement history available from 1 August 2025
Fromto
| Date / Time | Title | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 20 Aug 2026, 19:13 | Dimerix Receives US$10M Upfront Payment from Everest | Company Update | MS | 11001 | |
| 17 Aug 2026, 18:38 | Dimerix Assumes Sponsorship of US IND for New Asset DMX-652 | Company Update | MS | 11001 | |
| 6 Aug 2026, 18:17 | Dimerix Presents at Bioshares Summit 2026 | Presentations | MS | 03026 | |
| 30 July 2026, 18:49 | Dimerix Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19004, 19009 | |
| 27 July 2026, 18:36 | Dimerix to Present at TechKnow Invest Conference 2026 | Presentations | — | 03026 | |
| 23 July 2026, 18:46 | US Patent Granted for Dimerix New Asset DMX-652 | Company Update | MS | 11001 | |
| 17 July 2026, 19:03 | Dimerix Investor Webinar | Presentations | — | 03026, 14014 | |
| 17 July 2026, 19:03 | Dimerix Expands Pipeline with Acquisition of Phase 2 Asset | Company Update | MS | 11001 | |
| 17 July 2026, 19:01 | Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway | Capital Raising | MS | 03022, 09014 | |
| 15 July 2026, 18:42 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 9 July 2026, 18:46 | DMX-200 Available To Patients Via Post-Trial Access Pathways | Company Update | MS | 11001 | |
| 16 June 2026, 20:31 | Dimerix Investor Webinar | Presentations | — | 03026, 14014 | |
| 16 June 2026, 20:20 | Dimerix Licenses DMX200 to Everest for China and Asia Region | Company Update | MS | 09014, 11001 | |
| 15 June 2026, 19:13 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 30 Apr 2026, 19:13 | Dimerix Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19003, 19008 | |
| 28 Apr 2026, 20:26 | Dimerix Releases Investor Presentation and Video Recording | Company Update | — | 03026, 11001, 14014 | |
| 28 Apr 2026, 19:20 | ACTION3 Statistical Review Complete | Company Update | MS | 11001 | |
| 10 Apr 2026, 00:01 | Dimerix Singapore Investor Briefing | Company Administration | — | 12008 | |
| 16 Mar 2026, 20:20 | Dimerix Presents at Euroz Hartleys Institutional Conference | Presentations | — | 03026 | |
| 16 Mar 2026, 19:29 | Dimerix to Conduct Review of ACTION3 Statistical Assumptions | Company Update | MS | 11001 | |
| 10 Mar 2026, 20:21 | Dimerix Phase 3 Trial Last Patient Receives First Dose | Company Update | MS | 11001 | |
| 4 Mar 2026, 20:38 | Dimerix Invitation to Perth and Singapore Investor Briefings | Company Administration | — | 12008 | |
| 27 Feb 2026, 20:23 | Dimerix Presents at Oppenheimer Life Sciences Conference | Presentations | — | 03026 | |
| 26 Feb 2026, 20:30 | Appendix 4D and Half Year Financial Report | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 5 Feb 2026, 20:26 | Dimerix to Present at Euroz Hartleys Healthcare Forum 2026 | Presentations | — | 03026 | |
| 29 Jan 2026, 20:39 | Quarterly Appendix 4C and Activities Report | Quarterly Reports | MS | 19002, 19007 | |
| 21 Jan 2026, 19:28 | Appointment of CFO/Company Secretary | Company Administration | — | 12007, 12008 | |
| 12 Jan 2026, 19:28 | Clinical trial update at J.P. Morgan Healthcare Conference | Presentations | — | 03026 | |
| 24 Dec 2025, 19:36 | Dimerix receives input from FDA on ACTION3 trial endpoints | Company Update | — | 11001 | |
| 22 Dec 2025, 20:16 | BioMarin to acquire Dimerix US Partner, Amicus Therapeutics | Company Update | MS | 11001 | |
| 15 Dec 2025, 19:45 | DMX-200 ACTION3 Phase 3 Trial Completes Recruitment | Company Update | MS | 11001 | |
| 13 Dec 2025, 01:50 | Change of Director's Interest Notice - CS,HA,NW,SP & MD | Director Interests | — | 02009 | |
| 13 Dec 2025, 01:04 | Notification regarding unquoted securities - DXB | Other | — | 06021 | |
| 19 Nov 2025, 20:05 | Successful Completion of Planned IDMC Review | Company Update | MS | 11001 | |
| 19 Nov 2025, 03:58 | Results of AGM | Meetings & Governance | — | 08003 | |
| 18 Nov 2025, 23:58 | Chair Address and AGM Presentation | Presentations | — | 03026, 15002 | |
| 29 Oct 2025, 19:35 | Quarterly Appendix 4C and Activities Report | Quarterly Reports | MS | 19001, 19006 | |
| 23 Oct 2025, 03:20 | Cleansing Notice | Securities Administration | — | 06018 | |
| 23 Oct 2025, 03:13 | Application for quotation of securities - DXB | Other | — | 06020 | |
| 21 Oct 2025, 19:31 | Canaccord Drug & Device Conference Investor Presentation | Presentations | — | 03026 | |
| 16 Oct 2025, 20:03 | 2025 AGM Notice of Meeting, Letter of Access and Proxy | Meetings & Governance | — | 08001, 08004, 16002 | |
| 8 Oct 2025, 19:37 | Successful PARASOL Collaboration Data Analysis Outcome | Company Update | MS | 11001 | |
| 30 Sept 2025, 18:37 | DMX-200 receives Orphan Drug Designation in Japan | Company Update | MS | 11001 | |
| 19 Sept 2025, 19:32 | Notification of Date of 2025 AGM | Meetings & Governance | — | 08006, 12008 | |
| 3 Sept 2025, 19:07 | Investor Presentation | Presentations | — | 03026 | |
| 28 Aug 2025, 19:29 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 28 Aug 2025, 19:06 | Appendix 4E and 2025 Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 19 Aug 2025, 18:57 | Investor Presentation and Recording | Presentations | — | 03026 | |
| 13 Aug 2025, 01:08 | Cleansing Notice | Securities Administration | — | 06018 | |
| 13 Aug 2025, 01:02 | Application for quotation of securities - DXB | Other | — | 06020 |
1–50 of 51
1 / 2